MAK BIOTECH offers a growing portfolio of pharmaceutical formulations, including injectable products, manufactured at WHO-GMP compliant facilities.
Featured injectable formulations supplied through MAK BIOTECH for the domestic pharmaceutical market.
One of our leading and highest-selling products. Manufactured at a WHO-GMP compliant facility and intended for supply to approved pharmaceutical markets.
A Diclofenac Sodium injectable formulation offered as part of the MAK BIOTECH pharmaceutical portfolio.
A Pantoprazole 40 mg injectable formulation offered by MAK BIOTECH for pharmaceutical markets.
A Cefoperazone and Sulbactam injectable formulation included in the MAK BIOTECH pharmaceutical portfolio.
An Amoxicillin and Potassium Clavulanate injectable formulation offered by MAK BIOTECH.
Part of the MAK BIOTECH injectable pharmaceutical portfolio for approved pharmaceutical markets.
Products are manufactured at WHO-GMP compliant facilities and supplied by MAK BIOTECH. Product availability, registration and supply are subject to applicable regulatory requirements in the respective markets.
From essential medicines to specialized therapies — a comprehensive pharmaceutical portfolio for international markets.
MAK BIOTECH offers a comprehensive pharmaceutical portfolio for international markets, covering essential medicines, hospital care, critical care, surgical products, anti-infectives and specialized therapeutic segments. We work with qualified manufacturing partners to provide reliable, quality-assured pharmaceutical solutions tailored to the regulatory and market requirements of our international partners.
